COMPANY OVERVIEW:
Exchange: CANADA: CSE: OVAT USA: OTCQB: OVATF
Latest Company filings can be found on SEDAR
CIK: 0001515768
Fiscal Year End: 12/31
SIC – Industry Class: 2833 – medicinal and botanicals
Incorporated In: British Columbia, Canada
Year of Inc.: 2017
Ovation Science Inc.
Ovation Science Inc. is a research and development company focused on bringing real science to the cannabis industry by licensing its patented topical and transdermal products globally. Powered by its unique delivery system Invisicare®, Ovation Science is disrupting the market with highly effective products protected by patents and backed by science. Ovation’s out-licensing business model generates revenue from multiple revenue streams including development fees, licensing fees, on-going royalties and sales of Invisicare polymer to its licensees.
LICENSEES:
Ovation has the following licenses in place:
Planet 13 Holdings Inc., (our licensee for Nevada and Florida) a vertically integrated cannabis company, operates award-winning cultivation, production, and dispensaries in Las Vegas and Orange County, California. It also holds licenses in Florida and the Chicago-region of Illinois. Aiming to establish a global brand, Planet 13 focuses on top-tier dispensary services and innovative cannabis products. The company’s shares are traded on the Canadian Securities Exchange (CSE) under PLTH and on the OTCQX as PLNHF.
PA Options for Wellness, (our licensee for Pennsylvania) founded with a focus on research and patient outcomes, the company blends plant science with medicine to deliver innovative products to the medical market. Operating a 65,000 square foot advanced cannabis facility and six dispensaries in Pennsylvania, it emphasizes ethical standards and patient-centric care. Additionally, the company collaborates with medical experts and universities in the state for patient care and research advancements.
MidWest Roots, LLC, (our licensee for Missouri) operating one of Missouri’s largest facilities in Washington, MO, efficiently produces and distributes a wide range of cannabis products, including topicals, vape pens, edibles, and pills, with plans to introduce pre-rolled joints. Their strategic location near Interstates 44 and 70 enables quick statewide delivery.
Ovation Science Secures New Canadian Patent; Strengthening IP Position and Expanding Commercial Opportunities for Topical Cannabis Products
The patent, entitled “Composition and method for transdermal delivery of cannabidiol (CBD) and delta9-tetrahydrocannabinol (THC)” expands Ovation’s intellectual property protection beyond its previously issued U.S. patent and significantly strengthens the Company’s growing international patent portfolio.
Ovation Science Sees Expanded Opportunities for Its Topical Products Following U.S. Cannabis Rescheduling
Ovation Science Inc. (CSE: OVAT) is positioned to benefit from U.S. cannabis rescheduling, which reduces regulatory barriers for cannabinoid-based topicals. The company's patented Invisicare® technology delivers 82% CBD bioavailability—far exceeding the 2–3% of competing topicals—and its THC-free formulations may qualify for potential Medicare reimbursement, creating expanded licensing opportunities in the U.S. market.
Ovation Science Inc. Closes Private Placement
Ovation Science Inc. completed a non-brokered private placement to strengthen its financial position and support ongoing business development. The offering consisted of units made up of one common share and one warrant, with proceeds directed toward advancing company initiatives and general operations.
Ovation Science Inc. Announces Private Placement
Ovation Science Inc. announced a non-brokered private placement to support its business growth and general working capital needs. The offering includes units comprised of one common share and one warrant, with finder’s fees payable in cash and warrants.
Ovation Science and Skinvisible Strengthen Partnership in Obesity Market with New Cannabinoid Delivery Patents
Ovation Science and Skinvisible Pharmaceuticals have expanded their partnership to advance patent-pending Invisicare® cannabinoid delivery technology for obesity and metabolic health. The collaboration leverages THC-V research, new patent protection, and the growing US$150B obesity therapy market.
- Notice Of Annual General Meeting Of Shareholders To Be Held On Tuesday, November 25, 2025 And Information Circular (PDF, 417 KB)
- Form Of Proxy (PDF, 206 KB)
- Financial Statements Request Form (PDF, 156 KB)
